April 2016

New Product - Nucala

Nucala (mepolizumab) is a humanised IgG1 kappa monoclonal antibody directed against human interleukin-5 (IL-5). Mepolizumab inhibits the bioactivity of IL-5 with nanomolar potency by blocking the binding of IL-5 to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell surface, thereby inhibiting IL-5 signalling and reducing the production and survival of eosinophils. Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in patients aged 12 years and over. Nucala 100 mg powder for injection is available in vials of 1.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia┬áPty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629